Introduction: The renin angiotensin aldosterone system (RAAS) is a hormone system known for its role in regulating blood pressure and fluid balance. Numerous RAAS inhibitors routinely prescribed for hypertension have also beneficial effects in type 2 diabetes (T2D) prevention. RAAS components are expressed locally in many tissues, including adipose tissue and pancreas, where they exert metabolic effects through RAAS bioactive hormone angiotensin II (Ang II). Pancreatic beta cells are specialized insulin-producing cells; they have also developed endoplasmic reticulum (ER), which contributes to beta cell dysfunction, when proteins are misfolded in disease states such as T2D. However, no studies have investigated the relationship between RAAS and ER stress in beta cells as a mechanism linking pancreatic RAAS to T2D. Hence, we hypothesized that Ang II treatment of beta cells increases ER stress and inflammation leading to reduced insulin secretion. Methods: To test this hypothesis, we treated clonal INS-1E beta cells and human islets with Ang II and assessed changes in ER stress markers. INS-1E beta cells were also used for measuring insulin secretion and for assessing the effects of various RAAS and ER stress inhibitors. Results: We demonstrated that Ang II significantly increased the expression of ER stress genes such as Chop and Atf4 and reduced insulin secretion. Furthermore, inhibition of Ang II production with an angiotensin converting enzyme inhibitor (ACEi, captopril) significantly reduced ER stress. Moreover, the Ang II receptor blockade reduced ER stress significantly and rescued insulin secretion. Discussion: This research provides new mechanistic insight into the role of RAAS activation via ER stress on beta cell dysfunction and provides additional evidence for protective effects of RAAS inhibition in T2D.
Type 2 diabetes is an emerging epidemic and affects more than 25 million people in the United States. The Renin Angiotensin System (RAS) is classically known to regulate blood pressure and fluid balance. Interestingly, components of RAS, including the product angiotensin II (Ang II), which is the active hormone of this system, are expressed in both adipose tissues and pancreas. Studies conducted in our laboratory have shown that mice overexpressing RAS specifically in adipose tissue had insulin resistance, higher levels of inflammation, and endoplasmic reticulum (ER) stress. However, no studies have investigated the relationship between RAS and ER stress in beta cells. Hence, we hypothesized that activation of RAS in beta cells leads to increased ER stress and reduced insulin secretion. To test this hypothesis, we treated clonal beta cells with Ang II, and found that Ang II significantly increased the expression of ER stress genes such as CHOP and ATF4. In addition, Ang II treatments also reduced insulin secretion. Furthermore, inhibition of Ang II production in beta cells using an angiotensin converting enzyme inhibitor (ACEi) significantly reduced ER stress. Additionally, pharmacological inhibition of angiotensin type I and II receptors significantly reduced ER stress. These results indicate involvement of the RAS pathway in ER stress in pancreatic beta cells. We are currently determining effects of these RAS inhibitors on insulin secretion. In conclusion, this research will help better understand the role of RAS activation via ER stress on diabetes progression and may help develop new anti‐diabetes therapeutic targets.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.